Managing cardiotoxicity associated with immune checkpoint inhibitors

Immuno-oncology is a fast evolving field of cancer therapy and immune checkpoint inhibitors (ICIs) are clearly a breakthrough in this field. Cardiotoxicity with conventional anti-cancer therapies has been well studied in the past and clear guidelines for management of these side effects are availabl...

Full description

Bibliographic Details
Main Authors: Sireesha Upadhrasta, Hadi Elias, Keval Patel, Lei Zheng
Format: Article
Language:English
Published: KeAi Communications Co., Ltd. 2019-03-01
Series:Chronic Diseases and Translational Medicine
Online Access:http://www.sciencedirect.com/science/article/pii/S2095882X18301117
id doaj-b91444971101405b80c7c7722ba90885
record_format Article
spelling doaj-b91444971101405b80c7c7722ba908852021-04-02T13:16:36ZengKeAi Communications Co., Ltd.Chronic Diseases and Translational Medicine2095-882X2019-03-0151614Managing cardiotoxicity associated with immune checkpoint inhibitorsSireesha Upadhrasta0Hadi Elias1Keval Patel2Lei Zheng3Department of Internal Medicine, Saint Agnes Hospital, Baltimore, MD 21229, USADepartment of Internal Medicine, Saint Agnes Hospital, Baltimore, MD 21229, USADepartment of Internal Medicine, University of Maryland, Baltimore, MD 21201, USADepartments of Oncology and Surgery, The Pancreatic Cancer Precision Medicine Center of Excellence Program, The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, MD 21287, USA; Corresponding author. 1650 Orleans Street, CRB1, Room 351, Baltimore, MD 21287, USA. Fax: +1 410 614 8217.Immuno-oncology is a fast evolving field of cancer therapy and immune checkpoint inhibitors (ICIs) are clearly a breakthrough in this field. Cardiotoxicity with conventional anti-cancer therapies has been well studied in the past and clear guidelines for management of these side effects are available in the literature. However, cardiotoxicity with novel agents such as ICIs has been fairly under-reported and/or underestimated and we are yet to formulate clear guidelines for management of these rare side effects. In the last few years, there has been an overall increase in the number of cases of cardiotoxicity related to ICIs. In this literature review, we describe the mechanism of action of the most widely used ICIs and their related cardiotoxicities. The increase in number of case reports about the potential of cardiotoxicities with these novel agents clearly indicates the need for a new insight into the field of cardio-immuno-oncology. Keywords: Immune checkpoint inhibitor, Cardiotoxicity, Ipilimumab, Nivolumab, Pembrolizumabhttp://www.sciencedirect.com/science/article/pii/S2095882X18301117
collection DOAJ
language English
format Article
sources DOAJ
author Sireesha Upadhrasta
Hadi Elias
Keval Patel
Lei Zheng
spellingShingle Sireesha Upadhrasta
Hadi Elias
Keval Patel
Lei Zheng
Managing cardiotoxicity associated with immune checkpoint inhibitors
Chronic Diseases and Translational Medicine
author_facet Sireesha Upadhrasta
Hadi Elias
Keval Patel
Lei Zheng
author_sort Sireesha Upadhrasta
title Managing cardiotoxicity associated with immune checkpoint inhibitors
title_short Managing cardiotoxicity associated with immune checkpoint inhibitors
title_full Managing cardiotoxicity associated with immune checkpoint inhibitors
title_fullStr Managing cardiotoxicity associated with immune checkpoint inhibitors
title_full_unstemmed Managing cardiotoxicity associated with immune checkpoint inhibitors
title_sort managing cardiotoxicity associated with immune checkpoint inhibitors
publisher KeAi Communications Co., Ltd.
series Chronic Diseases and Translational Medicine
issn 2095-882X
publishDate 2019-03-01
description Immuno-oncology is a fast evolving field of cancer therapy and immune checkpoint inhibitors (ICIs) are clearly a breakthrough in this field. Cardiotoxicity with conventional anti-cancer therapies has been well studied in the past and clear guidelines for management of these side effects are available in the literature. However, cardiotoxicity with novel agents such as ICIs has been fairly under-reported and/or underestimated and we are yet to formulate clear guidelines for management of these rare side effects. In the last few years, there has been an overall increase in the number of cases of cardiotoxicity related to ICIs. In this literature review, we describe the mechanism of action of the most widely used ICIs and their related cardiotoxicities. The increase in number of case reports about the potential of cardiotoxicities with these novel agents clearly indicates the need for a new insight into the field of cardio-immuno-oncology. Keywords: Immune checkpoint inhibitor, Cardiotoxicity, Ipilimumab, Nivolumab, Pembrolizumab
url http://www.sciencedirect.com/science/article/pii/S2095882X18301117
work_keys_str_mv AT sireeshaupadhrasta managingcardiotoxicityassociatedwithimmunecheckpointinhibitors
AT hadielias managingcardiotoxicityassociatedwithimmunecheckpointinhibitors
AT kevalpatel managingcardiotoxicityassociatedwithimmunecheckpointinhibitors
AT leizheng managingcardiotoxicityassociatedwithimmunecheckpointinhibitors
_version_ 1721565615597027328